



A

LN229


eIF2



ATF6




GAPDH




U87


eIF2



ATF6



GAPDH



SNB19


eIF2



ATF6



GAPDH





**B**

**LN229**

**XBP1**



**GAPDH**



**U87**

**XBP1**


**GAPDH**



**SNB19**

**XBP1**

**GAPDH**



C

**LN229**

Treatment	RGD4C/AAVP-CMV-HSVtk			RGD4C/AAVP-Grp78-HSVtk		
control	2,65	2,50	2,99	4,40	3,51	3,98
TMZ	12,80	10,20	14,70	28,50	26,60	25,70
GCV	75,60	74,80	71,33	82,40	85,30	87,00
TMZ + GCV	78,80	82,60	81,90	88,20	91,00	90,20

**U87**

Treatment	RGD4C/AAVP-CMV-HSVtk			RGD4C/AAVP-Grp78-HSVtk		
control	12,00000	13,10000	12,80000	6,95000	7,74000	7,34000
TMZ	11,36667	10,26667	10,81667	10,95667	10,75667	10,85667
GCV	59,86667	54,46667	57,16667	63,55667	61,55667	62,55667
TMZ + GCV	67,06667	62,26667	64,66667	77,45667	74,35667	75,90667

**SNB19**

Treatment	RGD4C/AAVP-CMV-HSVtk			RGD4C/AAVP-Grp78-HSVtk		
control	4,94	5,26	5,17	9,45	11,20	9,35
TMZ	9,84	9,31	9,63	23,90	18,90	21,90
GCV	48,90	37,90	44,40	71,20	62,40	65,40
TMZ + GCV	59,60	64,10	59,30	82,20	83,20	89,60

**Figure 2- TMZ activation of the UPR pathway and subsequent enhancement of glioblastoma cell killing *in vitro* by the RGD4C/AAVP-Grp78-HSVtk and GCV**